India approves Eli Lilly’s Mounjaro KwikPen, a once-weekly injection for type 2 diabetes and obesity, offering dual hormone ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Boots Online Doctor has revealed the 'very common' side-effects of Mounjaro you need to know about after thousands of people ...

A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

Editor Sofia Lind questions the lack of planning, support and infrastructure for GPs among the rollout of tirzepatide in ...

In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...